Progress of angioimmunoblastic T-cell lymphoma
10.3760/cma.j.cn115356-20201225-00321
- VernacularTitle:血管免疫母细胞性T细胞淋巴瘤的研究进展
- Author:
Shuang DAI
1
;
Xiaoqin LIU
;
Jie ZHOU
;
Honge ZHANG
;
Ming JIANG
Author Information
1. 四川大学华西医院肺癌中心，成都 610041
- Keywords:
Molecular targeted therapy;
Angioimmunoblastic T-cell lymphoma;
Lymphoma, T-cell, peripheral;
Chemotherapy
- From:
Journal of Leukemia & Lymphoma
2021;30(10):630-633
- CountryChina
- Language:Chinese
-
Abstract:
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma (PTCL) that originates from follicular helper T cells (TFH). It has the highest incidence in PTCL which is second only to PTCL-not otherwise specified (PTCL-NOS). Its clinicopathological diagnosis is difficult, it is easy to be misdiagnosed and missed, and the prognosis is poor. This article reviews the pathogenesis, clinical and pathological characteristics as well as treatment progress of AITL, in order to provide a reasonable basis for clinical diagnosis and treatment of the disease.
